Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) COO Acquires $250,000.20 in Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) COO Denise P. Carter purchased 555,556 shares of the stock in a transaction dated Monday, December 23rd. The shares were acquired at an average price of $0.45 per share, with a total value of $250,000.20. Following the transaction, the chief operating officer now owns 602,648 shares in the company, valued at $271,191.60. This trade represents a 1,179.72 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Quoin Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ:QNRX traded down $0.01 during midday trading on Friday, hitting $0.55. The company had a trading volume of 553,804 shares, compared to its average volume of 1,118,553. Quoin Pharmaceuticals, Ltd. has a 12 month low of $0.43 and a 12 month high of $6.18. The firm has a fifty day simple moving average of $0.68 and a 200 day simple moving average of $0.63. The stock has a market cap of $2.78 million, a price-to-earnings ratio of -0.14 and a beta of 1.79.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.